Skip to content

US · AAPG · BIOTECHNOLOGY

Ascentage Pharma Group International (AAPG) intrinsic value and stock valuation

$11.97as of 2026-11-21 · Mkt cap 1.57B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Ascentage Pharma Group International DCF and intrinsic value

InvestorsCraft values AAPG with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from AAPG’s statements →

Ascentage Pharma Group International Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Suzhou, JS 215000 ascentage.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$558.5M+114% 5y CAGRd
20162025
Net income
-$-1.21B
20162025
Free cash flow
-$-1.2B
20162025
Total equity
$1.34B+9.5% 5y CAGRd
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$558.5M$980.7M$222M$209.7M$27.9M
Operating income-$-1.18B-$-369.73M-$-872.64M-$-849.81M-$-869.84M
Net income-$-1.21B-$-405.43M-$-925.64M-$-882.92M-$-782.42M
EPSd-$-13.58M-$-5.37M-$-52.47M-$-53.58M-$-49.18M
Operating cash flow-$-1.17B-$-111.36M-$-726.08M-$-653.91M-$-604.68M
Capital expenditure-$-27.57M-$-24.29M-$-56.84M-$-236.96M-$-436.63M
Free cash flow-$-1.2B-$-135.65M-$-782.92M-$-890.88M-$-1.04B
Total assets$3.97B$2.62B$2.5B$2.83B$2.94B
Total debt$1.98B$1.67B$1.8B$1.79B$1.08B
Net debt-$-490.68M$431.9M$726.3M$317.1M-$-622.6M
Total equity$1.34B$274.2M$70.6M$408.7M$1.23B
Cash and short-term investments$2.47B$1.24B$1.07B$1.48B$1.71B
Income statement
20252024202320222021
Revenue$558.5M$980.7M$222M$209.7M$27.9M
Cost of revenue$131.7M$29.1M$30.5M$22M$3.33M
Gross profit$426.8M$951.6M$191.4M$187.7M$24.6M
Research and development expenses$1.08B$947.3M$707M$743.1M$766.5M
Selling, general and administrative expenses$522.7M$383.1M$376.5M$328M$191.3M
Other expenses$0.00-$-9.07M-$-19.36M-$-33.6M$0.00
Operating expenses$1.61B$1.32B$1.06B$1.04B$957.8M
Cost and expenses$1.74B$1.35B$1.09B$1.06B$961.1M
Interest income$79.9M$37.8M$32.4M$9.73M$7.11M
Interest expense$52.6M$64.5M$96.1M$52.8M$16.7M
Depreciation and amortization$84.1M$93.2M$93.2M$47.4M$17.2M
Ebitda-$-1.1B-$-237.63M-$-743.61M-$-786.97M-$-798.34M
Operating income-$-1.18B-$-369.73M-$-872.64M-$-849.81M-$-869.84M
Total other income/expenses, net-$-23.21M-$-25.52M-$-60.23M-$-37.36M$37.6M
Income before tax-$-1.2B-$-395.25M-$-932.86M-$-887.17M-$-832.25M
Income tax expense$6.75M$10.4M-$-7.15M-$-4.25M-$-49.83M
Net income-$-1.21B-$-405.43M-$-925.64M-$-882.92M-$-782.42M
Weighted average shares outstanding$89M$75.5M$17.6M$16.5M$15.9M
Weighted average diluted shares outstanding$89M$75.5M$17.6M$16.5M$15.9M
Balance sheet
20252024202320222021
Cash and short-term investments$2.47B$1.24B$1.07B$1.48B$1.71B
Net receivables$253.1M$99.1M$163.5M$61.5M$54.1M
Inventory$28.6M$6.6M$16.2M$9.45M$3.93M
Total current assets$2.95B$1.47B$1.34B$1.64B$1.89B
Property, plant and equipment, net$829.6M$905.9M$957.2M$650M$854.3M
Goodwill and intangible assets$90.7M$100.7M$110.1M$109M$85.1M
Long-term investments$37.1M$33.9M$19M$18.5M$27.8M
Total non-current assets$1.02B$1.14B$1.16B$1.19B$1.05B
Total assets$3.97B$2.62B$2.5B$2.83B$2.94B
Accounts payable$106.8M$92M$72.4M$95.6M$70.9M
Short-term debt$1.22B$779.1M$616.4M$518.4M$49.5M
Deferred revenue$37.5M$54.1M$38.4M$24.4M$0.00
Total current liabilities$1.64B$1.17B$934.2M$881.2M$361.1M
Long-term debt$757.7M$889.4M$1.18B$1.27B$1.03B
Deferred revenue, non-current$216.9M$276M$287.6M$218.6M$243.3M
Total non-current liabilities$986.6M$1.18B$1.5B$1.54B$1.34B
Capital lease obligations$14.9M$30.2M$22.7M$17.2M$17.9M
Total liabilities$2.63B$2.34B$2.43B$2.42B$1.71B
Common stock$260K$210K$200K$180K$180K
Retained earnings$0.00-$-5.77B-$-5.37B-$-4.44B-$-3.56B
Accumulated other comprehensive income (loss)$1.33B-$-510.59M-$-504.46M-$-518.51M-$-550.95M
Total equity$1.34B$274.2M$70.6M$408.7M$1.23B
Total investments$37.1M$33.9M$19M$18.5M$27.8M
Total debt$1.98B$1.67B$1.8B$1.79B$1.08B
Net debt-$-490.68M$431.9M$726.3M$317.1M-$-622.6M
Cash flow statement
20252024202320222021
Net income-$-1.24B-$-395.25M-$-932.86M-$-887.17M-$-832.25M
Depreciation and amortization$86.5M$93.2M$93.2M$62.9M$28.3M
Stock-based compensation$20.9M$20.9M$31.5M$22.1M$47M
Change in working capital-$-143.5M$111M-$-9.15M$104.4M-$-74.91M
Accounts receivable-$-169.79M$62.8M-$-91.54M-$-390K-$-53.97M
Inventory-$-26.2M$9.57M-$-6.72M-$-5.52M-$-3.93M
Accounts payable$14.8M$19.5M-$-23.11M$24.7M$0.00
Net cash provided by operating activities-$-1.17B-$-111.36M-$-726.08M-$-653.91M-$-604.68M
Investments in property, plant and equipment-$-27.57M-$-24.29M-$-46.11M-$-203.29M-$-435.42M
Acquisitions, net-$-43.34M-$-25.52M-$-20M-$-20M-$-36.2M
Net cash used for investing activities-$-1B-$-362.04M$21.9M-$-384.61M-$-466.52M
Common stock issued$2.3B$533.9M$470.1M$0.00$1.3B
Common stock repurchased-$-9.04M$0.00-$-5.92M-$-26.78M-$-25.87M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$2.54B$314.8M$368.8M$619.3M$1.78B
Net change in cash$302.7M-$-144.95M-$-307.59M-$-361.25M$686.9M
Cash at end of period$1.2B$893.1M$1.04B$1.35B$1.71B
Operating cash flow-$-1.17B-$-111.36M-$-726.08M-$-653.91M-$-604.68M
Capital expenditure-$-27.57M-$-24.29M-$-56.84M-$-236.96M-$-436.63M
Free cash flow-$-1.2B-$-135.65M-$-782.92M-$-890.88M-$-1.04B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Ascentage Pharma Group International

        Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, including various cancers, chronic hepatitis B virus (HBV) infections, and age-related ailments. A cornerstone of its product pipeline is HQP1351, a BCR-ABL inhibitor specifically designed to address BCR-ABL1 mutants, notably those carrying the T315I mutation. The company's portfolio also encompasses APG-2575, an orally administered, selective Bcl-2 inhibitor aimed at treating hematologic malignancies and solid tumors. Another key asset, APG-115, is an oral small molecule that intervenes in MDM2-p53 protein-protein interactions, showing potential for both solid and blood cancers. Further bolstering its oncology efforts is APG-1252, a small molecule therapy engineered to reactivate programmed cell death (apoptosis) by dually inhibiting Bcl-2 and Bcl-xL proteins, targeting diseases such as small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumors, and non-Hodgkin's lymphoma. Beyond these, Ascentage is actively developing APG-1387, a small molecule apoptosis inhibitor designated for advanced solid tumors and chronic HBV. Its pipeline also features APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, a selective, orally available embryonic ectoderm development inhibitor; APG-265, an MDM2 protein degrader; and UBX1967/1325, which are additional Bcl-2 inhibitors. In addition to its core pharmaceutical activities, the company engages in medical research, clinical trial operations, venture capital investments, and offers rental and technology promotion services. Ascentage Pharma also cultivates strategic partnerships with various biotechnology and pharmaceutical companies, alongside research institutions. The company was founded in 2009.

        CEO
        Dajun Yang
        Employees
        767
        Beta
        0.66

        Explore

        Frequently asked questions

        What is the intrinsic value of Ascentage Pharma Group International (AAPG)?

        Ascentage Pharma Group International (AAPG) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is AAPG undervalued?

        AAPG trades at a price of $11.97 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.